<tr><td>
<!-- DAVID SULLIVAN TABLE -->
<table width="560" bgcolor="#FFFFFF"  cellpadding="0" cellspacing="0">
<!-- Top row space -->
  <tr>
    <td width="560" colspan="2" height="10"></td>
  </tr >

  <tr>
    <!-- <td width="10"></td> -->
    <td width="160" height="132" align="center" valign="middle">
      <a name="keech" id="keech"><img width="160" height="132" src="http://handtpreview.com/email_test/ACRE/images/DSullivan.jpg" /></a>
    </td>

    <td  width="160">
      <table width="400">
        <tr>
          <td height="25" style="color:#58595b; font-size:13px; font-weight:bold; padding-left:10px;" valign="top" >Identification and management of familial hypercholesterolaemia and the role of PCSK9 inhibition - Assoc. Professor David Sullivan</td>
        </tr>
        <tr>
          <td height="1"><img src="http://handtpreview.com/email_test/ACRE/images/hr3.jpg" /></td>
        </tr>
        <tr>
          <td width="400" valign="top" height="" style="padding-left:8px;padding-right:8px;padding-top:10px;padding-bottom:10px;color:#58595b; font-size:12px; line-height:18px;">
            Familial hypercholesterolaemia (FH) is the most common potentially fatal genetic condition and is grossly underdiagnosed in Australia and many other countries. While FH does have a poor prognosis, early identification and treatment has the potential to alter the course of the disease. The novel anti-PCSK9 antibodies represent a new treatment paradigm for FH patients. These provide another mechanism for cholesterol lowering â€“ different from and complementary to existing medications.
          </td>
        </tr>
      </table>
    </td>

  </tr>
  <!-- Bottom row space -->
  <tr>
    <td height="10"  colspan="2"></td>
  </tr >
</table>
 <!-- END DAVID SULLIVAN TABLE -->
</td></tr>